Urinary NMP22 for the detection of recurrence after transurethral resection of transitional cell carcinoma of the bladder: experience on 137 patients
- 1 November 1998
- Vol. 52 (5) , 793-796
- https://doi.org/10.1016/s0090-4295(98)00332-x
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- COMPARISON OF URINE COLLECTION METHODS FOR EVALUATING URINARY NUCLEAR MATRIX PROTEIN, NMP22, AS A TUMOR MARKERJournal of Urology, 1997
- Diagnostic Accuracy of Urinary Cytology, and Deoxyribonucleic Acid Flow Cytometry and Cytology on Bladder Washings During Followup for Bladder TumorsJournal of Urology, 1997
- Immunohistochemical analysis of proliferating cell nuclear antigen, p53 protein and nm23 protein, and nuclear DNA content in transitional cell carcinoma of the bladderCancer, 1996
- Urinary Nuclear Matrix Protein as a Marker for Transitional Cell Carcinoma of the Urinary TractJournal of Urology, 1996
- Use of a New Tumor Marker, Urinary NMP22, in the Detection of Occult or Rapidly Recurring Transitional Cell Carcinoma of the Urinary Tract Following Surgical TreatmentJournal of Urology, 1996
- Initial Evaluation of the Bladder Tumor Antigen Test in Superficial Bladder CancerJournal of Urology, 1996
- Utilization of Nuclear Matrix Proteins for Cancer DiagnosisCritical Reviews™ in Eukaryotic Gene Expression, 1996
- Results of a Multicenter Trial using the BTA Test to Monitor for and Diagnose Recurrent Bladder CancerJournal of Urology, 1995
- Current status of urinary cytology in the evaluation of bladder neoplasmsHuman Pathology, 1990